Clinical trial
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque…
NCT00230529 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00230529 |
|---|---|
| Title | A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis |
| Official title | A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE) Induction Therapy in Patients With Plaque-type Psoriasis |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | infliximab |
| Enrollment | 249 |
| Completion | Jan 1, 2003 |
| First posted | Oct 3, 2005 |
| Last update posted | Jun 9, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: